Research Papers:
Locally advanced cervical cancer with bladder invasion: clinical outcomes and predictive factors for vesicovaginal fistulae
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1698 views | HTML 3897 views | ?
Abstract
Roger Sun1,2, Ines Koubaa3, Elaine Johanna Limkin1,2, Isabelle Dumas4, Enrica Bentivegna5, Eduardo Castanon6, Sébastien Gouy5, Cynthia Baratiny1, Fyo Monnot1, Pierre Maroun1, Samy Ammari3, Elise Zareski3, Corinne Balleyguier3, Éric Deutsch1,2,7, Philippe Morice5,7, Christine Haie-Meder1 and Cyrus Chargari1,2,8,9
1Department of Radiotherapy, Gustave Roussy Cancer Campus, Villejuif, France
2INSERM U1030 Molecular Radiotherapy, Gustave Roussy Cancer Campus, Villejuif, France
3Department of Radiology, Gustave Roussy Cancer Campus, Villejuif, France
4Department of Medical Physics, Gustave Roussy Cancer Campus, Villejuif, France
5Department of Surgery, Gustave Roussy Cancer Campus, Villejuif, France
6Department of Drug development, Gustave Roussy Cancer Campus, Villejuif, France
7Université Paris Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France
8Institut de Recherche Biomédicale des Armées, Brétigny-sur-Orge, France
9French Military Health Service Academy, Ecole du Val-de-Grace, Paris, France
Correspondence to:
Cyrus Chargari, email: [email protected]
Keywords: cervical cancer; locally advanced; brachytherapy; bladder invasion; vesicovaginal fistula
Received: August 29, 2017 Accepted: January 01, 2018 Published: January 18, 2018
ABSTRACT
Objective: We report outcomes of cervical cancer patients with bladder invasion (CCBI) at diagnosis, with focus on the incidence and predictive factors of vesicovaginal fistula (VVF).
Results: Seventy-one patients were identified. Twenty-one (30%) had para-aortic nodal involvement. Eight had VVF at diagnosis. With a mean follow-up time of 34.2 months (range: 1.9 months–14.8 years), among 63 patients without VVF at diagnosis, 15 (24%) developed VVF. A VVF occurred in 19% of patients without local relapses (9/48) and 40% of patients with local relapse (6/15). Two-year overall survival (OS), disease-free survival (DFS) and local control rates were 56.4% (95% CI: 44.1–67.9%), 39.1% (95% CI: 28.1–51.4%) and 63.8% (95% CI: 50.4–75.4%), respectively. Para-aortic nodes were associated with poorer OS (adjusted HR = 3.78, P-value = 0.001). In multivariate analysis, anterior tumor necrosis on baseline MRI was associated with VVF formation (63% vs 0% at 1 year, adjusted-HR = 34.13, 95% CI: 4.07–286, P-value = 0.001), as well as the height of the bladder wall involvement of >26 mm (adjusted-HR = 5.08, 95% CI: 1.38–18.64, P-value = 0.014).
Conclusions: A curative intent strategy including brachytherapy is feasible in patients with CCBI, with VVF occurrence in 24% of the patients. MRI patterns help predicting VVF occurrence.
Methods: Patients with locally advanced CCBI treated with (chemo)radiation ± brachytherapy in our institute from 1989 to 2015 were analyzed. Reviews of baseline magnetic resonance imaging (MRI) scans were carried out blind to clinical data, retrieving potential parameters correlated to VVF formation (including necrosis and tumor volume).
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24271